- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01797536
The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)
September 27, 2018 updated by: Merck Sharp & Dohme LLC
A Three-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-8742
The purpose of this study is to evaluate the pharmacokinetics (PK) profile of elbasvir (MK-8742) after a single dose to participants with mild, moderate, or severe hepatic insufficiency compared with healthy controls.
Study Overview
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Call for Information (Investigational Site 0003)
-
Orlando, Florida, United States, 32809
- Call for Information (Investigational Site 0001)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Body mass index (BMI) 19 - 40 kg/m^2, inclusive
- In good health based on medical history, physical examination, vital signs, and laboratory safety tests
- No clinically significant abnormality on electrocardiogram (ECG)
- For participants with hepatic insufficiency only, diagnosis of chronic (> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due to any cause
- For participants with hepatic insufficiency only, score on the Child-Pugh scale must range from 5 to 6 for mild hepatic insufficiency, from 7 to 9 for moderate hepatic insufficiency, and from 10 to 15 for severe hepatic insufficiency
- Females of childbearing potential must be either be sexually inactive (abstinent) for 14 days before study drug administration and throughout the study or be using an acceptable method of birth control
- Females of non-childbearing potential must have undergone sterilization procedures at least 6 months before Study Day 1
- Non-vasectomized males must agree to use a condom with spermicide or abstain from sexual intercourse during the study and for 3 months after study drug administration
- Ability to swallow multiple capsules
Exclusion Criteria:
- Previously enrolled in this study
- Mentally or legally incapacitated, significant emotional problems at the time of screening or expected during the conduct of the study, or a history of a clinically significant psychiatric disorder over the last 5 years
- History or presence of significant cardiovascular, pulmonary, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological disease
- History of any illness that might confound the results of the study or pose an additional risk to the participant by participating in the study
- For participants with hepatic insufficiency only, estimated creatinine clearance (CrCl) ≤30 mL/min based on the Cockcroft-Gault equation at screening
- History or presence of drug abuse within the past 2 years
- For healthy participants only, history of alcoholism within the past 2 years
- Females who are pregnant or lactating
- Positive results for the urine drug screen at screening or check-in
- Positive results at screening or history of human immunodeficiency virus (HIV) or untreated hepatitis C virus (HCV); HCV ribonucleic acid (RNA)-negative participants documented to be cured following anti-HCV treatment are eligible
- For healthy participants only, positive results at screening for hepatitis B surface antigen (HBsAg)
- Use of any drugs or substances known to be strong inhibitors of cytochrome P450 3A4 (CYP3A4) enzymes and/or P-glycoprotein (P-gp) or any inhibitors of organic anion transporting peptide 1B (OATP1B) within 14 days or 5-times the half-life of the product (for healthy participants) or which cannot be discontinued at least 14 days or 5 times the half-life of the product (for hepatic insufficiency participants) before study drug administration and throughout the study
- Use of any drugs or substances known to be strong inducers of CYP3A4 enzymes and/or P-gp, including St-John's Wort or rifampin, within 28 days or 5 times the half-life of the product before study drug administration
- Currently use of any medication or substance which cannot be discontinued or maintained at a steady dose and regimen at least 14 days before study drug administration and throughout the study
- For healthy participants only, on a special diet within 28 days before study drug administration
- Blood donation >500 mL or significant blood loss within 56 days before study drug administration
- Plasma donation within 7 days before study drug administration
- Participation in another clinical study within 28 days before study drug administration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mild Hepatic Insufficiency
Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with mild hepatic insufficiency, defined as a score of 5 to 6 on the Child-Pugh scale
|
|
Experimental: Moderate Hepatic Insufficiency
Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with moderate hepatic insufficiency, defined as a score of 7 to 9 on the Child-Pugh scale
|
|
Experimental: Severe Hepatic Insufficiency
Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with severe hepatic insufficiency, defined as a score of 10 to 15 on the Child-Pugh scale
|
|
Experimental: Healthy Participants
Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants matched to the mean of all hepatic insufficiency participants for age, gender, and weight
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve From 0 to Infinity (AUC0-inf) of Elbasvir
Time Frame: Predose and Hours 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 96, 144, and 168
|
Blood samples were collected at predose and Hours 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 96, 144, and 168 to determine the AUC0-inf of elbasvir.
|
Predose and Hours 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 96, 144, and 168
|
Area Under the Curve From 0 to 24 Hours (AUC0-24hr) of Elbasvir
Time Frame: Predose and Hours 0.5, 1, 2, 3, 4, , 6, 8, 12, 16, and 24
|
Blood samples were collected at predose and Hours 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 24 to determine the AUC0-24hr of elbasvir.
|
Predose and Hours 0.5, 1, 2, 3, 4, , 6, 8, 12, 16, and 24
|
Maximum Concentration (Cmax) of Elbasvir
Time Frame: Predose and Hours 0.5, 1, 2, 3, 4, , 6, 8, 12, 16, 24, 48, 96, 144, and 168
|
Blood samples were collected at predose and Hours 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 96, 144, and 168 to determine the Cmax of Elbasvir.
|
Predose and Hours 0.5, 1, 2, 3, 4, , 6, 8, 12, 16, 24, 48, 96, 144, and 168
|
Concentration at 24 Hours (C24) After Dosing Elbasvir
Time Frame: Hour 24
|
Blood samples were collected at predose and Hours 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 24, to determine the concentration of elbasvir at Hour 24 was determined.
|
Hour 24
|
Time to Maximum Concentration (Tmax) of Elbasvir
Time Frame: Predose and Hours 0.5, 1, 2, 3, 4, , 6, 8, 12, 16, 24, 48, 96, 144, and 168
|
Blood samples were collected at predose and Hours 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 96, 144, and 168 to determine the maximum concentration (Cmax) of elbasvir.
The time to reach Cmax (Tmax) was determined.
|
Predose and Hours 0.5, 1, 2, 3, 4, , 6, 8, 12, 16, 24, 48, 96, 144, and 168
|
Apparent Terminal Half-Life (t1/2) of Elbasvir
Time Frame: Predose and Hours 0.5, 1, 2, 3, 4, , 6, 8, 12, 16, 24, 48, 96, 144, and 168
|
Blood samples were collected at predose and Hours 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 96, 144, and 168 to determine the t1/2 of elbasvir.
|
Predose and Hours 0.5, 1, 2, 3, 4, , 6, 8, 12, 16, 24, 48, 96, 144, and 168
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 6, 2013
Primary Completion (Actual)
August 20, 2014
Study Completion (Actual)
August 20, 2014
Study Registration Dates
First Submitted
February 20, 2013
First Submitted That Met QC Criteria
February 20, 2013
First Posted (Estimate)
February 22, 2013
Study Record Updates
Last Update Posted (Actual)
October 25, 2018
Last Update Submitted That Met QC Criteria
September 27, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8742-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Insufficiency
-
PfizerCompletedHealthy, Hepatic InsufficiencyUnited States
-
BeiGeneCompletedHepatic Insufficiency & Healthy SubjectsUnited States
-
BayerCompletedHepatic Insufficiency, Renal InsufficiencyGermany, Romania
-
Cardiox CorporationTerminatedHepatic Failure
-
Novartis PharmaceuticalsCompletedHepatic FailureUnited States
-
Centre Hospitalier Universitaire de NiceCompleted
-
Biotie Therapies Inc.Acorda TherapeuticsTerminatedHepatic ImpairmentUnited States
-
PfizerMedivation, Inc.Completed
-
Assistance Publique - Hôpitaux de ParisUnknownFulminating Hepatic FailureFrance
-
National Taiwan University HospitalUnknownLiver Failure | Critical CareTaiwan
Clinical Trials on Elbasvir
-
Merck Sharp & Dohme LLCCompleted
-
National Cheng-Kung University HospitalMerck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Institut de Médecine et d'Epidémiologie Appliquée...Merck Sharp & Dohme LLC; Institut National de la Santé Et de la Recherche Médicale...Completed
-
King Fahad Medical CityCompletedHepatitis C, ChronicSaudi Arabia
-
University Hospital, ToulouseMSD FranceCompletedChronic Kidney Diseases | Hepatitis CFrance
-
Bayside HealthMerck Sharp & Dohme LLC; Austin Hospital, Melbourne AustraliaWithdrawnHepatocellular Carcinoma | Hepatitis C | Hepatoma | Liver Cell Carcinoma
-
Erasmus Medical CenterCompletedHepatitis C | Human Immunodeficiency Virus | Acute Hepatitis CNetherlands, Belgium
-
University Hospital, Clermont-FerrandMerck Sharp & Dohme LLCCompleted